Literature DB >> 2616032

Reduced GABA uptake sites in the temporal lobe in schizophrenia.

M D Simpson1, P Slater, J F Deakin, M C Royston, W J Skan.   

Abstract

The binding of [3H]nipecotic acid, a ligand for labelling GABA uptake sites in brain, was measured in left and right frontal cortex, polar temporal cortex, hippocampus and amygdala from control and schizophrenic postmortem brains. In schizophrenic brains, single concentration [3H]nipecotic acid binding was reduced bilaterally in amygdala and hippocampus and on the left side only in polar temporal cortex. These data suggest that GABA neurones are involved in the cerebral atrophy of schizophrenia and, in agreement with other studies, that this process is most pronounced in left temporal cortex.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2616032     DOI: 10.1016/0304-3940(89)90819-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  34 in total

Review 1.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

Review 2.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 3.  Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies.

Authors:  Ana D Stan; David A Lewis
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

Review 4.  Searching for unique endophenotypes for schizophrenia and bipolar disorder within neural circuits and their molecular regulatory mechanisms.

Authors:  Francine M Benes
Journal:  Schizophr Bull       Date:  2007-06-16       Impact factor: 9.306

Review 5.  rTMS strategies for the study and treatment of schizophrenia: a review.

Authors:  Arielle D Stanford; Zafar Sharif; Cheryl Corcoran; Nina Urban; Dolores Malaspina; Sarah H Lisanby
Journal:  Int J Neuropsychopharmacol       Date:  2008-02-01       Impact factor: 5.176

Review 6.  Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.

Authors:  John E Lisman; Joseph T Coyle; Robert W Green; Daniel C Javitt; Francine M Benes; Stephan Heckers; Anthony A Grace
Journal:  Trends Neurosci       Date:  2008-04-07       Impact factor: 13.837

7.  Altered ratios of alternatively spliced long and short gamma2 subunit mRNAs of the gamma-amino butyrate type A receptor in prefrontal cortex of schizophrenics.

Authors:  M M Huntsman; B V Tran; S G Potkin; W E Bunney; E G Jones
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

8.  Amygdala abnormalities in first-degree relatives of individuals with schizophrenia unmasked by benzodiazepine challenge.

Authors:  Daniel H Wolf; Theodore D Satterthwaite; James Loughead; Amy Pinkham; Eve Overton; Mark A Elliott; Gersham W Dent; Mark A Smith; Ruben C Gur; Raquel E Gur
Journal:  Psychopharmacology (Berl)       Date:  2011-05-21       Impact factor: 4.530

Review 9.  Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia.

Authors:  David A Lewis; Takanori Hashimoto; Harvey M Morris
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

10.  Perinatal phencyclidine administration decreases the density of cortical interneurons and increases the expression of neuregulin-1.

Authors:  Nevena V Radonjić; Igor Jakovcevski; Vladimir Bumbaširević; Nataša D Petronijević
Journal:  Psychopharmacology (Berl)       Date:  2013-02-05       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.